Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2015 from OUS - Molecular characterization of mesenchymal cancer development

8 publications found

Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015)
Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
Genome Res, 25 (6), 897-906
DOI 10.1101/gr.185793.114, PubMed 25800674

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
Genome Biol, 16, 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ et al. (2015)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 25 (6), 814-24
DOI 10.1101/gr.190470.115, PubMed 25963125

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
Genomic landscape of liposarcoma
Oncotarget, 6 (40), 42429-44
DOI 10.18632/oncotarget.6464, PubMed 26643872

Myklebost O (2015)
Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls
Per Med, 12 (6), 593-602
DOI 10.2217/pme.15.20, PubMed 29750616

Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK (2015)
Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death
Mol Cancer, 14, 14
DOI 10.1186/s12943-014-0278-9, PubMed 25623255

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
Blood Cancer J, 5, e299
DOI 10.1038/bcj.2015.24, PubMed 25794135

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
Oncotarget, 6 (4), 2451-65
DOI 10.18632/oncotarget.3235, PubMed 25669981

 
Page visits: 70271